Clinical reference Biomarker Directory
Back to directory

Zinc transporter 8

Emerging

ZnT8 autoantibodies are now a standard component of the type 1 diabetes diagnostic autoantibody panel, improving detection rates.

Also known as ZnT8 ZnT8A (autoantibody) SLC30A8
In plain language

ZnT8 is found on the cells that make insulin, and antibodies against it are now checked alongside other standard tests to diagnose type 1 diabetes, especially helping catch cases that the older antibody tests alone would have missed.

Biomarker & context

Zinc transporter 8 (ZnT8) is a protein expressed on pancreatic beta cells involved in insulin storage and secretion; autoantibodies against it are relevant to type 1 diabetes autoimmunity.

What it indicates

ZnT8 autoantibodies are now a standard part of the type 1 diabetes autoantibody panel (alongside GAD, IA-2, and insulin antibodies) — adding ZnT8 testing increases detection rates up to roughly 98% in some populations.

Diagnosis & clinical testing

Measured via ELISA as part of a multi-antibody type 1 diabetes panel; ZnT8 testing can identify autoimmune diabetes in patients who test negative on the older standard antibodies alone, which is clinically useful for correctly distinguishing autoimmune from monogenic diabetes.

Guiding treatment

In patients with new-onset diabetes and negative standard antibodies, adding ZnT8 testing (alongside a type 1 diabetes genetic risk score) can help exclude the need for unnecessary monogenic diabetes genetic testing, streamlining the diagnostic workup.

Clinical significance

Helps distinguish autoimmune type 1 diabetes from monogenic diabetes, avoiding unnecessary genetic testing in some patients.

References
  1. PMC. (2020). Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes-Genetic Risk Score Can Exclude Individuals with Type 1 Diabetes from Inappropriate Genetic Testing for Monogenic Diabetes.